Abstract
Anxiety is a serious and frequent complication in Parkinson’s disease (PD) that significantly affects the quality of life of patients. Multiple neuroanatomical, experimental, and clinical studies suggest its close association with axial disturbances. However, whether this relation applies for PD patients (commonly suffering from axial difficulties, such as balance and gait disturbance) has not been properly tested yet. The purpose of this study was to determine whether PD patients suffering from axial symptoms have higher levels of anxiety than others and to identify other factors associated with anxiety–axial connections. In this questionnaire study, 212 patients with PD were assessed by standardized scales, such as Hamilton Anxiety Scale, Montgomery–Asberg Depression Rating Scale, Montreal Cognitive Assessment, examining their mood and cognitive status. These data were correlated to dominant motor symptoms of these patients, such as tremor, rigidity, bradykinesia, and axial symptoms. Unlike other motor symptoms, only axial symptoms showed to be significantly related to higher levels of anxiety. The patients suffering from anxiety and axial problems have also shown significantly higher depression levels. Axial disturbances are related to higher anxiety levels in PD patients. It is crucial to pay high attention to symptoms of anxiety in patients having postural instability or gait disorder. Further clinical studies are desirable to investigate new, practical implications of anxiety–axial connection to provide complex management options of these serious symptoms.
Similar content being viewed by others
References
Adkin AL, Frank JS, Jog MS (2003) Fear of falling and postural control in Parkinson’s disease. Mov Disord 18:496–502
American Psychiatric Association (2013) Diagnostic and Statistical Manual of Mental Disorders, Fifth edn. American Psychiatric Publishing, Arlington, VA, p 189
Anguenot A, Loll PY, Neau JP, Ingrand P, Gil R (2002) Depression and Parkinson’s Disease: study of a series of 135 Parkinson’s patients. Can J Neurol Sci 29:139–146
Balaban CD (1996) Vestibular nucleus projections to the parabrachial nucleus in rabbits: implications for vestibular influences on the autonomic nervous system. Exp Brain Res 108:367–381
Balaban CD, Thayer JF (2001) Neurological bases for balance-anxiety links. J Anxiety Disord 15:53–79
Bares M, Rektorova I, Jech R, Farnikova K, Roth J, Ruzicka E, Kanovsky P, Rektor I, Pavlik T, Uhlirova L, Vydlak J (2012) Does WOQ-9 help to recognize symptoms of non-motor wearing-off in Parkinson’s disease? J Neural Trans (Vienna) 119:373–380
Bart O, Bar-Haim Y, Weizman E, Levin M, Sadeh A, Mintz M (2009) Balance treatment ameliorates anxiety and increases self-esteem in children with comorbid anxiety and balance disorder. Res Dev Disabil 30:486–495
Bloem BR, Grimbergen YA, Cramer M, Willemsen M, Zwinderman AH (2001) Prospective assessment of falls in Parkinson’s disease. J Neurol 248:950–958
Bostantjopoulou S, Katsarou Z, Karakasis C, Peitsidou E, Milioni D, Rossopoulos N (2013) Evaluation of non-motor symptoms in Parkinson’s disease: an underestimated necessity. Hippokratia 17:214–219
Brown RG, Landau S, Hindle JV, Playfer J, Samuel M, Wilson KC, Hurt CS, Anderson RJ, Carnell J, Dickinson L, Gibson G, van Schaick R, Sellwood K, Thomas BA, Burn DJ, PROMS-PD Study Group (2011) Depression and anxiety related subtypes in Parkinson’s disease. J Neurol Neurosurg Psychiatry 82:803–809
Bryant MS, Rintala DH, Hou JG, Protas EJ (2014) Influence of fear of falling on gait and balance in Parkinson’s disease. Disabil Rehabil 36:744–748
Burn DJ, Landau S, Hindle JV, Samuel M, Wilson KC, Hurt CS, Brown RG, PROMS-PD Study Group (2012) Parkinson’s disease motor subtypes and mood. Mov Disord 27:379–386
Casacchia M, Zamponi A, Squitieri G, Meco G (1975) Treatment of anxiety in Parkinson’s disease with bromazepam. Riv Neurol 45:326–338
Charney DS, Deutch A (1996) A functional neuroanatomy of anxiety and fear: implications for the pathophysiology and treatment of anxiety disorders. Crit Rev Neurobiol 10:419–446
Chen JJ, Marsh L (2014) Anxiety in Parkinson’s disease: identification and management. Ther Adv Neurol Disord 7:52–59
Davison GC (2008) Abnormal Psychology. Veronica Visentin, Toronto, p 154
Dissanayaka NN, Sellbach A, Matheson S, O’Sullivan JD, Silburn PA, Byrne GJ, Marsh R, Mellick GD (2010) Anxiety disorders in Parkinson’s disease: prevalence and risk factors. Mov Disord 25:838–845
Dissanayaka NN, White E, O’Sullivan JD, Marsh R, Pachana NA, Byrne GJ (2014) The clinical spectrum of anxiety in Parkinson’s disease. Mov Disord 29:967–975
Ehgoetz Martens KA, Ellard CG, Almeida QJ (2014) Does anxiety cause freezing of gait in Parkinson’s disease? PLoS One 9:e106561
Ehgoetz Martens KA, Ellard CG, Almeida QJ (2015a) Anxiety-provoked gait changes are selectively dopa-responsive in Parkinson’s disease. Eur J Neurosci 42:2028–2035
Ehgoetz Martens KA, Ellard CG, Almeida QJ (2015b) Virtually induced threat in Parkinson’s: dopaminergic interactions between anxiety and sensory-perceptual processing while walking. Neuropsychologia 79:322–331
Elbers RG, van Wegen EE, Verhoef J, Kwakkel G (2013) Is gait speed a valid measure to predict community ambulation in patients with Parkinson’s disease? J Rehabil Med 45:370–375
Ellis T, Boudreau JK, DeAngelis TR, Brown LE, Cavanaugh JT, Earhart GM, Ford MP, Foreman KB, Dibble LE (2013) Barriers to exercise in people with Parkinson disease. Phys Ther 93:628–636
Eysenck MW, MacLeod C, Mathews A (1987) Cognitive functioning and anxiety. Psychol Res 49:189–195
Franchignoni F, Martignoni E, Ferriero G, Pasetti C (2005) Balance and fear of falling in Parkinson’s disease. Parkinsonism Relat Disord 11:427–433
Gallagher DA, Schrag A (2012) Psychosis, apathy, depression and anxiety in Parkinson’s disease. Neurobiol Dis 46:581–589
Goddard AW, Charney DS (1997) Toward an integrated neurobiology of panic disorder. J Clin Psychiatry 58(Suppl 2):4–11 (discussion 11–2)
Goetz CG (2010) New developments in depression, anxiety, compulsiveness, and hallucinations in Parkinson’s disease. Mov Disord 25(Suppl 1):S104–S109
Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins GT, Counsell C, Giladi N, Holloway RG, Moore CG, Wenning GK, Yahr MD, Seidl L, Movement Disorder Society Task Force on Rating Scales for Parkinson’s Disease (2004) Movement disorder society task force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord 19:1020–1028
Hamilton M (1959) The assessment of anxiety states by rating. Br J Med Psychol 32:50–55
Hely MA, Morris JG, Traficante R, Reid WG, O’Sullivan DJ, Williamson PM (1999) The sydney multicentre study of Parkinson’s disease: progression and mortality at 10 years. J Neurol Neurosurg Psychiatry 67:300–307
Jankovic J (2008) Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 79:368–376
Jiang SM, Yuan YS, Tong Q, Zhang L, Xu QR, Ding J, Zhang KZ (2015) The association between clinically relevant anxiety and other non-motor symptoms in Parkinson’s disease. Neurol Sci 36:2105–2109
Kandiah N, Zhang A, Cenina AR, Au WL, Nadkarni N, Tan LC (2014) Montreal Cognitive Assessment for the screening and prediction of cognitive decline in early Parkinson’s disease. Parkinsonism Relat Disord 20:1145–1148
Ketharanathan T, Hanwella R, Weerasundera R, de Silva VA (2016) Diagnostic validity and factor analysis of Montgomery-Asberg Depression Rating Scale in Parkinson disease population. J Geriatr Psychiatry Neurol 29:115–119
Kummer A, Cardoso F, Teixeira AL (2008) Frequency of social phobia and psychometric properties of the Liebowitz social anxiety scale in Parkinson’s disease. Mov Disord 23:1739–1743
Kummer A, Cardoso F, Teixeira AL (2009) Suicidal ideation in Parkinson’s disease. CNS Spectr 14:431–436
Kurlan R (2005) “Fear of falling” gait: a potentially reversible psychogenic gait disorder. Cogn Behav Neurol 18:171–172
Leentjens AF, Dujardin K, Marsh L, Martinez-Martin P, Richard IH, Starkstein SE, Weintraub D, Sampaio C, Poewe W, Rascol O, Stebbins GT, Goetz CG (2008) Anxiety rating scales in Parkinson’s disease: critique and recommendations. Mov Disord 23:2015–2025
Leentjens AF, Dujardin K, Marsh L, Martinez-Martin P, Richard IH, Starkstein SE (2011a) Symptomatology and markers of anxiety disorders in Parkinson’s disease: a cross-sectional study. Mov Disord 26:484–492
Leentjens AF, Dujardin K, Marsh L, Richard IH, Starkstein SE, Martinez-Martin P (2011b) Anxiety rating scales in Parkinson’s disease: a validation study of the Hamilton anxiety rating scale, the Beck anxiety inventory, and the hospital anxiety and depression scale. Mov Disord 26:407–415
Lindholm B, Hagell P, Hansson O, Nilsson MH (2014) Factors associated with fear of falling in people with Parkinson’s disease. BMC Neurol 14:19
Lohnes CA, Earhart GM (2010) External validation of abbreviated versions of the activities-specific balance confidence scale in Parkinson’s disease. Mov Disord 25:485–489
Mak MK, Pang MY, Mok V (2012) Gait difficulty, postural instability, and muscle weakness are associated with fear of falling in people with Parkinson’s disease. Parkinsons Dis 2012:901721
Marinus J, Leentjens AF, Visser M, Stiggelbout AM, van Hilten JJ (2002) Evaluation of the hospital anxiety and depression scale in patients with Parkinson’s disease. Clin Neuropharmacol 25:318–324
Martinez-Martin P, Rojo-Abuin JM, Dujardin K, Pontone GM, Weintraub D, Forjaz MJ, Starkstein S, Leentjens AF (2013) Designing a new scale to measure anxiety symptoms in Parkinson’s disease: item selection based on canonical correlation analysis. Eur J Neurol 20:1198–1203
Matheson SF, Byrne GJ, Dissanayaka NN, Pachana NA, Mellick GD, O’Sullivan JD, Silburn PA, Sellbach A, Marsh R (2012) Validity and reliability of the Geriatric Anxiety Inventory in Parkinson’s disease. Australas J Ageing 31:13–16
McDowell I (2006) Measuring health: a guide to rating scales and questionnaires. Oxford University Press, Oxford
Melton LJ, Leibson CL, Achenbach SJ, Bower JH, Maraganore DM, Oberg AL, Rocca WA (2006) Fracture risk after the diagnosis of Parkinson’s disease: influence of concomitant dementia. Mov Disord 21:1361–1367
Menza M, Marin H, Kaufman K, Mark M, Lauritano M (2004) Citalopram treatment of depression in Parkinson’s disease: the impact on anxiety, disability, and cognition. J Neuropsychiatry Clin Neurosci 16:315–319
Mondolo F, Jahanshahi M, Grana A, Biasutti E, Cacciatori E, Di Benedetto P (2007) Evaluation of anxiety in Parkinson’s disease with some commonly used rating scales. Neurol Sci 28:270–275
Muller-Thomsen T, Arlt S, Mann U, Mass R, Ganzer S (2005) Detecting depression in Alzheimer’s disease: evaluation of four different scales. Arch Clin Neuropsychol 20:271–276
Negre-Pages L, Grandjean H, Lapeyre-Mestre M, Montastruc JL, Fourrier A, Lepine JP, Rascol O, DoPaMiP Study Group (2010) Anxious and depressive symptoms in Parkinson’s disease: the French cross-sectionnal DoPaMiP study. Mov Disord 25:157–166
Nilsson MH, Hariz GM, Iwarsson S, Hagell P (2012) Walking ability is a major contributor to fear of falling in people with Parkinson’s disease: implications for rehabilitation. Parkinsons Dis 2012:713236
Pasman EP, Murnaghan CD, Bloem BR, Carpenter MG (2011) Balance problems with Parkinson’s disease: are they anxiety-dependent? Neuroscience 177:283–291
Pontone GM, Williams JR, Anderson KE, Chase G, Goldstein SA, Grill S, Hirsch ES, Lehmann S, Little JT, Margolis RL, Rabins PV, Weiss HD, Marsh L (2009) Prevalence of anxiety disorders and anxiety subtypes in patients with Parkinson’s disease. Mov Disord 24:1333–1338
Pont-Sunyer C, Hotter A, Gaig C, Seppi K, Compta Y, Katzenschlager R, Mas N, Hofeneder D, Brucke T, Bayes A, Wenzel K, Infante J, Zach H, Pirker W, Posada IJ, Alvarez R, Ispierto L, De Fabregues O, Callen A, Palasi A, Aguilar M, Marti MJ, Valldeoriola F, Salamero M, Poewe W, Tolosa E (2015) The onset of nonmotor symptoms in Parkinson’s disease (the ONSET PD study). Mov Disord 30:229–237
Prediger RD, Matheus FC, Schwarzbold ML, Lima MM, Vital MA (2012) Anxiety in Parkinson’s disease: a critical review of experimental and clinical studies. Neuropharmacology 62:115–124
Rahman S, Griffin HJ, Quinn NP, Jahanshahi M (2008) Quality of life in Parkinson’s disease: the relative importance of the symptoms. Mov Disord 23:1428–1434
Reppa GP (2013) The effects of a new program (balance & reform) on trait anxiety and self- esteem: a pilot study. Proc Soc Behav Sci 84:230–232
Rinalduzzi S, Trompetto C, Marinelli L, Alibardi A, Missori P, Fattapposta F, Pierelli F, Curra A (2015) Balance dysfunction in Parkinson’s disease. Biomed Res Int 2015:434683
Rosenhan DL, Seligman M, Walke EF (2001) Abnormal psychology. W W Norton & Co Inc, New York
Routh LC, Black JL, Ahlskog JE (1987) Parkinson’s disease complicated by anxiety. Mayo Clin Proc 62:733–735
Sagna A, Gallo JJ, Pontone GM (2014) Systematic review of factors associated with depression and anxiety disorders among older adults with Parkinson’s disease. Parkinsonism Relat Disord 20:708–715
Scalzo PL, Flores CR, Marques JR, Robini SC, Teixeira AL (2012) Impact of changes in balance and walking capacity on the quality of life in patients with Parkinson’s disease. Arq Neuropsiquiatr 70:119–124
Shefer S, Gordon C, Avraham KB, Mintz M (2015) Balance deficit enhances anxiety and balance training decreases anxiety in vestibular mutant mice. Behav Brain Res 276:76–83
Shulman L, Singer C, Liefert R, Mellman T, Weiner W (1996) Therapeutic effects of sertraline in patients with Parkinson’s disease. Movement disorders 11:12
Siemers ER, Shekhar A, Quaid K, Dickson H (1993) Anxiety and motor performance in Parkinson’s disease. Mov Disord 8:501–506
Sumec R, Filip P, Sheardova K, Bares M (2015) Psychological benefits of nonpharmacological methods aimed for improving balance in Parkinson’s disease: a systematic review. Behav Neurol 2015:620674
Tarczy M, Szombathelyi E (1998) Depression in Parkinson’s disease with special regard to anxiety: experiences with paroxetine treatment. Mov Disord 13:275
Thomas AA, Rogers JM, Amick MM, Friedman JH (2010) Falls and the falls efficacy scale in Parkinson’s disease. J Neurol 257:1124–1128
Troeung L, Egan SJ, Gasson N (2013) A meta-analysis of randomised placebo-controlled treatment trials for depression and anxiety in Parkinson’s disease. PLoS One 8:e79510
Vaccarino AL, Evans KR, Sills TL, Kalali AH (2008) Symptoms of anxiety in depression: assessment of item performance of the hamilton anxiety rating scale in patients with depression. Depress Anxiety 25:1006–1013
Williams JB, Kobak KA (2008) Development and reliability of a structured interview guide for the montgomery asberg depression rating scale (SIGMA). Br J Psychiatry 192:52–58
Acknowledgements
This work was supported by Novartis s.r.o., Czech Republic.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
No compensation was provided to Dr. Šumec for his writing of this manuscript. No compensation was provided to Drs. Rektorová, Jech, Menšíková, Roth, Růžička, Sochorová, Dušek, Kaňovský, Rektor, Pavlík, Filip, and Bareš for their revision of the manuscript. Drs. Bareš, Rektorová, Jech, Menšíková, Roth, and Růžička received compensation from Novartis for their sites’ conduct of the study.
Financial disclosures
Rastislav Šumec, MD: Employment: University Hospital of St. Anne, Brno, Czech Republic, Masaryk University; ICRC-International Clinical Research Center. Irena Rektorová, MD, PhD: Employment: Faculty of Medicine, Masaryk University, Brno, Czech Republic, Central European Institute of Technology, CEITEC MU, Masaryk University, Brno, Czech Republic, St Anne’s University Hospital, Brno, Czech Republic. Consultancies: none. Advisory boards: none. Honoraria: none. Grants: JPND grants (Joint Programme in Neurodegeneration), Grants of the Czech Ministry of Health, mentor for a postdoc Marie Curie grant/SoMoPro. Clinical trials: none for the last 2 years. Robert Jech, MD, PhD: Employment: Charles University in Prague, General Teaching hospital, Prague, Na Homolce Hospital, Prague. Honoraria: co-organized received consultancy fees and organized teaching courses for Abbvie, Cardion, Ipsen and Medtronic. Kateřina Menšíková, MD: Employment: Palacky University in Olomouc, General University Hospital in Olomouc. Honoraria: Lectures for GSK and Novartis. Jan Roth, MD, CSc.: Employment: Department of Neurology and Center of Clinical Neuroscience, Charles University in Prague, 1st Faculty of Medicine and General University Hospital in Prague, Katerinska 30, 12000 Prague 2, Czech Republic. Honoraria: from Abbvie, UCB, AOP Orphan. Grants:PRVOUK-P26/LF1/4, NT11190-6/2010, NT11331-6/2010, KONTAKT II LH13256, Česko- Norský výzkumný program 7F14308. Clinical Trials: Teva-Legato. Evžen Růžička, MD, DrSc., FCMA. Employment: Charles University in Prague, General University Hospital in Prague. Grants from: EU Horizon 2020, Grant agency of the Czech Republic, Czech Ministry of Health and Charles University in Prague. In the preceding 12 months, he has received honoraria or consulting fees from Merz. Clinical trials: Kyowa, Solvay, Abbvie. Dana Sochorová: Employment: ICRC-International Clinical Research Center. Grants: ICRC project of specific research MUNI/A/1270/2015. Ladislav Dušek, Employment: Institute of Biostatistics and Analyses, Masaryk University, Brno. Petr Kaňovský, MD, CSc.: Employment: Palacky University in Olomouc, University Hospital Olomouc. Consultancies: Merz, Allergan, Medtronic. Advisory boards: Merz. Honoraria: Merz, Ipsen, Medtronic, Lundbeck, Actavis. Grants: IGA MZ CR NT-14407, NT-13575, NT-12221, AZV NV15-31921A. Clinical trials: Kyowa, Merz, Biogen, Novartis, ONO Pharma, Merck Serono. Ivan Rektor, MD, CSc.: Employment: Masaryk University in Brno, St. Anne’s Hospital Brno. Grants: CEITEC. Tomáš Pavlík, MSc, PhD: Employment: Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic. Honoraria: Sanofi-Aventis. Pavel Filip, MD: Employment: University Hospital of St. Anne, Brno, Czech Republic, Masaryk University; Clinical trials: investigator in INREST 1VIT14037. Martin Bareš, MD, PhD: Employment: Masaryk University Anne’s Hospital Brno. Advisory boards: Boehringer Ingelheim. Honoraria: personal compensations for activities with Ipsen, Neomed, Medtronic, Abbvie. Grants: Czech Ministry of Health, Masaryk University. Clinical Trials: Kyowa, Abbvie.
Ethical standards
This study has been approved by ethics committee of St. Anne’s University Hospitál and has therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. All participants gave their informed consent prior to their inclusion in the study.
Appendix
Appendix
The other members of the EWO Study Group are: Marek Baláž, Brno; Jan Bartoník, Kroměříž; Petra Bártová, Ostrava; Michal Bednář, Hradec Králové; Jiří Blažej, Kutná Hora; Martina Bočková, Brno; Jaroslava Budínská, Litoměřice; Vladko Bydžovský, České Budějovice; Eliška Debefová, Kroměříž; Václav Dostál, Pardubice; Klára Drugová, Praha; Petr Dušek, Praha; Naděžda Fišerová, Vyškov; Eva Formánková, České Budějovice; Martin Havlán, Chodov; Petra Havránková, Praha; Lenka Hlinková, Praha; Jakub Hort, Praha; Jaromír Houser, České Budějovice; Pavel Houška, Strakonice; Lucie Hrušková, Karlovy Vary; Helena Hyclová, Kladno; Zuzana Chovancová, Olomouc; Helena Chybová, Náchod; Michael Inneman, Kladno; Pavel Janouškovec, Plzeň; Markéta Jirásková, Praha; Kristina Jonsztová, Karviná; Zbyněk Kalita, Zlín; Gabriela Kamencová, Vsetín; Dagmar Kazdová, Žďár nad Sázavou; Jiří Klempíř, Praha; Lucie Kozlová, Ústínad Labem; Andrea Krompolcová, Nový Jičín; Margareta Krupová, Nový Jičín; Blanka Kykalová, Praha; Jana Letáková, Praha; Pavel Lindovský, Praha; Vojtěch Mach, Plzeň; Taťjana Majorová, Praha; Jarmila Maňhalov, Trutnov; Zuzana Matoušová, Praha; Hana Melšová, Děčín; Blanka Mistríková, Zlín; Jiří Neumann, Chomutov; Martin Nevrlý, Olomouc; Dana Nováčková, Český Krumlov; Lucie Nováková, Praha; Václav Ondřich, Brno; Eva Paseková, Praha; Kateřina Pavlosková, Ostrava; Lenka Peníšková, Liberec; Jan Peregrin, Praha; Alena Pospíšilová, Praha; Irena Pozděnová, Plzeň; Jozef Pribula, Litoměřice; Petr Procházka, Zlín; Jaroslav Rach, Strakonice; Daniel Rosol, Prachatice; Danuše Roubcová, Ostrava; Tereza Serranová, Praha; Světlana Skutilová, Brno; Stanislav Slavík, Most; Jana Sobotová, Plzeň; Helena Straková, Chomutov; Hana Streitová, Brno; Lenka Svatíková, Přerov; Jindra Svátová, Praha; Věnceslava Svobodová, Praha; Dáša Sýkorová, Ostrava; Radim Szotkowski, Přerov; Monika Šimečková, Kadaň; Václav Tomášek, Praha; Zdeněk Topinka, Kolín; Leona Uhlířová, Praha; Olga Ulmanová, Praha; Martina Vančurová, Teplice; Tomáš Vodvářka, Ostrava; Hana Vránová, Olomouc; Jaroslav Vydlák, Praha; Dana Vyskočilová, Praha; Oldřich Vyšata, Rychnov nad Kněžnou; Antonín Wierer, České Budějovice; Kateřina Zárubová, Praha; Richard Zindr, Karlovy Vary.
Rights and permissions
About this article
Cite this article
Šumec, R., Rektorová, I., Jech, R. et al. Motion and emotion: anxiety–axial connections in Parkinson’s disease. J Neural Transm 124, 369–377 (2017). https://doi.org/10.1007/s00702-016-1652-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00702-016-1652-0